# A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

> **NCT05543174** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 7 (actual)

## Conditions studied

- Alagille Syndrome (ALGS)

## Interventions

- **DRUG:** TAK-625

## Key facts

- **NCT ID:** NCT05543174
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-16
- **Primary completion:** 2023-10-25
- **Final completion:** 2025-07-25
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05543174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05543174, "A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05543174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*